Invited Lectures

  1. “COVID-19 Pandemic and Vaccination”. Virtual Lecture on SARS-CoV-2 Vaccination, University of Cyprus. Nicosia, Cyprus, August 31, 2021
  2. “Implications of SARS-CoV-2 Mutations in the Efficacy of COVID-19 Vaccines”. Lecture on COVID-19 Lordos Hotels, Larnaca. Larnaca, Cyprus, July 20, 2021
  3. “Upcoming SARS-CoV-2 Mutations and the Post-COVID-19 Era”. Timios Stavros Hospital, Larnaca. Larnaca, Cyprus, July 8, 2021
  4. “A comprehensive Molecular Epidemiology Analysis of the SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic”. 3rd Lecture Series “Excellence in Biology”, Cypriot Biological Society. Virtual Conference. Cyprus, April 17, 2021
  5. “Molecular Epidemiology of SARS-CoV-2 Infection in Cyprus: Genetic, Phylogenetic, and Phylogeographic Analysis of Clinical Samples from April 2020 to January 2021”. University of Cyprus Press Conference on COVID-19. Nicosia, Cyprus, February 19, 2021
  6. “Longitudinal HIV-1 Phylogenetic and Phylodynamic Transmission Analyses in Cyprus: The Cypriot HIV-1 Transmission Cohort Study (CHICS)”. 4th Annual Health Care Congress-2019. Marrakech, Morocco, April 27, 2019
  7. “Phylogenetic and Phylodynamic Analyses of the Cypriot HIV-1 Transmission Cohort Study (CHICS) from 1986 to 2012”. European Society for Translational Antiviral Research (ESAR), Scientific Spring Meeting. Rome, Italy, May 29, 2018
  8. “Scholarship and Leadership in Science: The Art and the Politics”. National Honor Society (NHS) Induction Ceremony, American International School in Cyprus (AISC). Nicosia, Cyprus, March 22, 2018
  9. “Current Therapies for HIV-1 Infection”. 3rd Pancyprian Student Conference on Molecular Biology, Biochemistry, Genetics and Cell Biology. Nicosia, Cyprus, February 17, 2018
  10. “Host and Viral Factors in HIV-1 Disease”. 6th Conference of the Cyprus Society of Human Genetics. Nicosia, Cyprus, November 24, 2017.
  11. “HIV Disease: From Biology to Chemotherapeutics and Beyond”. 5th International Multi-thematic Scientific Bio-Medical Congress. Nicosia, Cyprus, November 4, 2017.
  12. “The Development of Vaccines Using Genetically Engineered Inoviruses”. 15th Annual Summit on Vaccines and Immunization. Berlin, Germany, February 20, 2017.
  13. “Engineering Antigen-Displayed Phage as Vaccines”. 4th World Congress on Targeting Infectious Diseases Phage Therapy. Paris, France, June 3, 2016.
  14. “Transmission Patterns of Concurrent HIV-1 Subtype Epidemics Circulating in Cyprus ”. European Society for Antiviral Research (ESAR). Rome, Italy, May 24, 2016.
  15. “Novel Vaccines Utilizing Antigen-Displayed Inoviral Vectors”. 7th Middle East-Global Summit on Vaccines & Vaccination. Dubai, UAE, September 28, 2015.
  16. “Re-Engineering Inoviruses to Advance Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines”. The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem. Jerusalem, Israel, May 28, 2015.
  17. “Development of Prophylactic Vaccines Against HIV-1”. Open University in London, London, UK, March 19, 2015.
  18. “HIV-1 Disease: From Biology to Chemotherapeutics to Vaccines”. 10th Hellenic Conference in Virology, Athens, Greece, February 28, 2015.
  19. “Viral Attack and Cellular Defense: Role of Human Genetics in the Biology of HIV-1 ”. Annual Conference of Cyprus Society of Human Genetics, Nicosia, Cyprus, January 9, 2014.
  20. “Molecular Epidemiology of HCV Infection in Cyprus”. Annual Conference of Hepatology, Nicosia, Cyprus, March 3, 2012.
  21. “Molecular Evolution of Human Immunodeficiency Virus Type-1 (HIV-1)”. 7th Congress of Biology Society, Limassol, Cyprus, April 6, 2011.
  22. “Monitoring the HIV-1 Disease in Cyprus (1986 – 2010)”. 5th Congress of Clinical Chemistry and Laboratory Medicine, Limassol, Cyprus, March 19, 2011.
  23. “Viral Universe”. The American International School in Cyprus, Nicosia, Cyprus, December 9, 2010
  24. “High Points of Virology Presented at the 17th Conference on Retroviruses and Opportunistic Infection (CROI)”. 16th International Symposium on HIV and Emerging Infectious Diseases, Marseille, France, March 26, 2010
  25. “HIV-1 Integrase Inhibitors: Role of Natural Genetic Diversity of Drug Efficacy and Resistance”. 2nd International Conference on Drug Discovery and Therapy, Dubai, United Arab Emirates, February 4, 2010
  26. “Spread of HCV among Intravenous Drug Users in Cyprus”, Press Conference on Infectious Diseases Associated with Intravenous Drug Users, Nicosia, Cyprus, December 15, 2009
  27. “Charles Darwin and the Theory of Evolution”, 200th Anniversary of Darwin’s Birth, Pallouriotissa Lyceum, Nicosia, Cyprus, December 11, 2009
  28. “Understanding the Molecular Basis of HIV Integrase Inhibitors by Molecular Modeling: Implications of HIV Natural Genetic Diversity on Drug Efficacy and Resistance”. Israeli AIDS Medical Society Conference, Ramot, Israel, November 27, 2009
  29. “Implications of HIV-1 Natural Genetic Diversity on Structure-Based Drug Design and Development of Drug Resistance”. Erasmus University Medical Center, Rotterdam, The Netherlands, October 29, 2008
  30. “Structured-Based Computational Analysis of the Implications of Subtype Specific Polymorphisms within M Group Strains on the Efficacy of HIV-1 Integrase Inhibitors”. 5th EuropeHIVResistance Meeting, Budapest, Hungary, March 25, 2008
  31. “Implications of Viral and Host Factors in HIV-1 Transmission and Pathogenesis”. Medical Society, Downing College of the University of Cambridge, UK, February 28, 2007
  32. “HIV-1 Infection in Cyprus: Where is Coming from and Where is Going to”. 2007 World AIDS Day, Nicosia, Cyprus, December 1, 2007
  33. “Quantifying Minority HIV-1 Drug Resistant Strains by Novel Assays Using Allele-Discriminating Polymerizing Molecular Beacons and Real-Time PCR Technologies”. 2007 4th EuropeHIVResistance Meeting, Zeist, Netherlands, October 16, 2007
  34. “Molecular Epidemiology of HIV-1 Infection in Cyprus and Spread of Resistance to Antiretroviral Drugs”. 2006 World AIDS Day, Nicosia, Cyprus, December 1, 2006
  35. “Molecular Beacon Technology: Host and Viral Factors in HIV-1 Transmission and Pathogenesis”. Department of Mechanical Engineering, University of Cyprus, November 1, 2006
  36. “Reservoir and Resistance: Implications of Cellular HIV-1 DNA Load in Resistance and Efficacy of Antiretroviral Therapy”. 2nd EuropeHIVresistance Meeting. Zandvoort, Netherlands, October 10, 2006
  37. “Host and Viral Correlates of HIV-1 Transmission and Disease Progression”. US National Institute of Health, DHHS 2006 NIAID Research Conference, Opatija, Croatia, 2006
  38. “Advances in HIV Virology”. 14th International Symposium on HIV and Emerging Infectious Diseases, Tulon, France, 2006
  39. “Multi-Allelic Detection of the Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) Using ‘Sloppy’ Molecular Beacons: A ‘Molecular Shotgun’ Approach of Recognizing a Moving Genetic Target”. 8th Hellenic Symposium of Virology, Thessalonica, Greece, 2006
  40. “HIV-1 Cellular Viral Load Pre- and Post-Antiretroviral Therapy”. 1st EuropeHIVresistance Meeting. Monte Carlo, Monaco, March 27, 2006
  41. “Cellular Viral Load Pre- and Post-Antiretroviral Therapy”. 2nd International Workshop on HIV Persistence During Therapy. Saint Martin, French West Indies, December 7, 2005
  42. “Η Επόμενη Πανδημία Γρίπης (Human Influenza Virus): Μαθήματα από την Φυσική Ιστορία της HIV Λοίμωξης”. Science Day, University of Cyprus. Nicosia, Cyprus, November 19, 2005
  43. “Implications of HIV-1 Cellular Viral Load in Resistance”. 9th SPREAD European Coordinators Meeting. Vinkeveen, Netherlands, November 1, 2005
  44. “Φυσική Ιστορία της λοίμωξης HIV: Από που Έρχεται και που Πηγαίνει”. Science Day, University of Cyprus. Nicosia, Cyprus, October 8, 2005
  45. “Natural History of HIV: The Role of Host Genetics in HIV Transmission and Disease Progression”. Open University of Greek Society in London. London, United Kingdom, April 21, 2005
  46. “Host Genetics in HIV Transmission and Pathogenesis”. 15th International AIDS Conference. Bangkok, Thailand, July 13, 2004
  47. “Implications of Host Genetics in HIV-1 Disease”. University of Toronto. Toronto, Canada, June 15, 2004
  48. “Detection & Quantification of the SARS-associated coronavirus”. 13th International Symposium on HIV & Emerging Infectious Diseases. Tulon, France, June 5, 2004
  49. “Impact of HIV-1 Cellular Viral Load on the Progression of HIV-1 Disease”. 1st International Workshop on HIV Persistence during Therapy. French West Indies, December 10, 2003
  50. “The Impact of Human Allelic Variation on HIV Disease”. The International Center for Public Health. Newark, USA, June 11, 2003
  51. “Rapid Molecular Identification of Pathogenic Agents: Detection of Bacillus anthracis (anthrax) Strains in Clinical Samples”. 4th Biomedical Symposium. Limassol, Cyprus, March 15, 2003
  52. “Viral and Host Determinants on HIV-1 Disease”. 4th Biomedical Symposium. Limassol, Cyprus, March 15, 2003
  53. “Molecular Beacons: An Emerging Technology for Molecular Diagnosis”. Hellenic Pasteur Institute. Athens, Greece, February 5, 2003
  54. “Impact of Cellular HIV-1 Viral Load on the Progression of HIV-1 Disease”. XIV International AIDS Conference. Barcelona, Spain, July 11, 2002
  55. “Use of Molecular Beacons and Multi-Allelic Rapid-Cycle Real-Time PCR for Detection of and Discrimination between Virulent Bacillus anthracis and Other Bacillus Isolates in Clinical Samples”. Conference for Bio-terrorism in Greece. Hellenic Center for Infectious Disease Control of the Ministry of Health. Athens, Greece, May 10, 2002
  56. “Quantification of Minor Populations of Drug-Resistant HIV-1 Isolates by a Selective Amplification Assay Using Fluorescence-Based Real-Time PCR and Allele-Discriminating Oligonucleotides”. 3rd International Workshop on Structured Treatment Interruptions. Montreal, Canada, March 23, 2002
  57. “Molecular Detection and Genetic Characterization of Bacillus anthracis (anthrax) by a Rapid Assay Using Real-Time PCR and Molecular Beacons”. Center for Disease Control, Ministry of Health, Greece. Athens, Greece, November 21, 2001
  58. “The Implications of Host Genetics for the Transmission of HIV-1 and the Progression of HIV-1 Disease”. 6th Hellenic Biomedical Congress. Athens, Greece. October 12, 2000
  59. “Natural History of HIV and the Historical Advancements on Treatment and Vaccine Development”. 3rd Symposium for Clinical Laboratory Subjects. Limassol, Cyprus, March 18, 2000
  60. “Impact of Natural CCR5 Polymorphisms and Recent Thymic Emigrants on HIV-1 Disease”. University of Massachusetts Medical School Worcester, USA. January 12, 2000
  61. “Effects of CCR5 Allelic Variants and the Thymus on HIV-1 Disease”. College of Physicians and Surgeons, Columbia University. New York, USA, December 13, 1999
  62. “Molecular Beacons: Gene Quantification and Allele Discrimination”. ViroLogic South San Francisco, USA, November 5, 1999
  63. “The role of Alpha-1 T cell Receptor Excisional Circles (α1 TREC) in HIV-Disease Progression”. Viral Epidemiology Branch, National Cancer Institute. Frederick, USA, July 20, 1999
  64. “Impact of Chemokine Receptor Polymorphisms on Vertical Transmission”. Teratology Society: HIV Infection During Pregnancy. Keystone, USA, June 29, 1999
  65. “Spectral Genotyping of Chemokine Receptor Polymorphisms”. CCR5 AIDS Symposium: Genetic Consequences of CCR5 Promoter Variants on AIDS at The National Cancer Institute. Frederick, USA, April 30, 1999
  66. “The Role of Natural Chemokine Receptor Polymorphisms in HIV-1-Induced Disease”. Second National Symposium on AIDS and Sexually Transmitted Decease Athens, Greece. April 23, 1999
  67. “Human Genetic Variation and HIV”. Baruch College, City University of New York. New York, USA. February 18, 1999
  68. “Polymorphisms in the Regulatory Region of the CCR5 Influence Perinatal Transmission of HIV”. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2, 1999
  69. “Polymorphisms in the Regulatory Region of the CCR5: Influence on Perinatal Transmission of HIV-1”. Pediatric AIDS Clinical Trial Group (ACTG). Washington DC, USA, December 7, 1998
  70. “The Impact of Chemokine Receptor Polymorphisms on HIV Disease”. The Treatment Action Group. New York, USA, October 6, 1998
  71. “HIV-1 Variation”. The Sophie Davis School of Biomedical Education, City University of New York. New York, USA, June 3, 1996
  72. “Molecular Epidemiology of HIV infection in Cyprus”. Gregorian AIDS Foundation. Nicosia, Cyprus, March 15, 1996
  73. “Neutralization Serotypes of HIV-1”. First National Symposium on AIDS and Sexually Transmitted Decease. Thessaloniki, Greece, March 8, 1996
  74. “Global Genetic Variability of HIV-1: Implications for Vaccine Development”. Baruch College, City University of New York. New York, USA, February 29, 1996
  75. “Genetic Subtypes and Neutralization Serotypes of HIV-1”
    Public Health Research Institute. New York, USA, February 6, 1996
  76. “Genetic Analysis of HIV-1 Strains from Patients in Cyprus”. 3rd Cypriot Conference on AIDS. Nicosia, Cyprus. December 3, 1995